CertaraCERT Market cap $1.77B
About: Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Employees: 1,391
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
0% less funds holding
Funds holding: 217 [Q1] → 216 (-1) [Q2]
0.77% less ownership
Funds ownership: 75.33% [Q1] → 74.55% (-0.77%) [Q2]
3% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 29
19% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 86
23% less capital invested
Capital invested by funds: $2.15B [Q1] → $1.66B (-$493M) [Q2]
41% less call options, than puts
Call options by funds: $133K | Put options by funds: $226K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
UBS Dan Leonard 44% 1-year accuracy 4 / 9 met price target | 46%upside $16 | Buy Upgraded | 27 Sept 2024 |
UBS Dan Leonard 44% 1-year accuracy 4 / 9 met price target | 46%upside $16 | Neutral Maintained | 7 Aug 2024 |
Baird Joe Vruwink 45% 1-year accuracy 10 / 22 met price target | 64%upside $18 | Neutral Maintained | 7 Aug 2024 |
Keybanc Scott Schoenhaus 24% 1-year accuracy 6 / 25 met price target | 82%upside $20 | Overweight Maintained | 11 Jul 2024 |
Financial journalist opinion
Based on 3 articles about CERT published over the past 30 days